EA202092087A1 - Анализы для выявления нейродегенеративных заболеваний - Google Patents

Анализы для выявления нейродегенеративных заболеваний

Info

Publication number
EA202092087A1
EA202092087A1 EA202092087A EA202092087A EA202092087A1 EA 202092087 A1 EA202092087 A1 EA 202092087A1 EA 202092087 A EA202092087 A EA 202092087A EA 202092087 A EA202092087 A EA 202092087A EA 202092087 A1 EA202092087 A1 EA 202092087A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
analysis
neurodegenerative diseases
detecting
detecting neurodegenerative
Prior art date
Application number
EA202092087A
Other languages
English (en)
Inventor
Хартмут Кристиан Колб
Галлен Триана-Балтцер
Джон Ренделл Слеммон
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA202092087A1 publication Critical patent/EA202092087A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4005—Concentrating samples by transferring a selected component through a membrane
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Предложены способы измерения количества фосфорилированного по одному или множеству сайтов p217+ тау-белка в пробе. Кроме того, предложены способы обнаружения или диагностики таупатий, способы определения эффективности лечения таупатии и способы определения приемлемости пациента для терапии антителом к p217+ тау-белку. Дополнительно описаны антитела для применения в способах и наборы, содержащие такие антитела.
EA202092087A 2018-03-05 2019-03-04 Анализы для выявления нейродегенеративных заболеваний EA202092087A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862638524P 2018-03-05 2018-03-05
PCT/IB2019/051747 WO2019171258A1 (en) 2018-03-05 2019-03-04 Assays to detect neurodegeneration

Publications (1)

Publication Number Publication Date
EA202092087A1 true EA202092087A1 (ru) 2020-11-17

Family

ID=67768541

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092087A EA202092087A1 (ru) 2018-03-05 2019-03-04 Анализы для выявления нейродегенеративных заболеваний

Country Status (16)

Country Link
US (3) US20200408781A1 (ru)
EP (1) EP3762414A4 (ru)
JP (2) JP7399096B2 (ru)
KR (1) KR20200130354A (ru)
CN (1) CN112105640A (ru)
AU (1) AU2019232630A1 (ru)
BR (1) BR112020018193A2 (ru)
CA (1) CA3093198A1 (ru)
EA (1) EA202092087A1 (ru)
IL (1) IL277077A (ru)
JO (1) JOP20200216A1 (ru)
MA (1) MA53338A (ru)
MX (1) MX2020009278A (ru)
PH (1) PH12020551371A1 (ru)
SG (1) SG11202008574VA (ru)
WO (1) WO2019171258A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4040153A4 (en) * 2019-09-30 2023-07-26 Nipro Corporation PROCEDURE FOR DETECTING TAU PROTEIN USING A BLOOD SAMPLE AS SAMPLE
US20220018857A1 (en) * 2020-07-14 2022-01-20 Janssen Pharmaceutica Nv Blood-based assay for detecting tauopathy or amyloidogenic disease
EP4232155A1 (en) * 2020-10-26 2023-08-30 JANSSEN Pharmaceutica NV Methods of reducing tau in human subjects
CN116635414A (zh) * 2021-02-19 2023-08-22 卫材R&D管理有限公司 抗pt217 tau抗体
WO2023056410A1 (en) * 2021-10-01 2023-04-06 Integrated Neurologics LLC Methods and devices for detecting cerebrospinal fluid leakage
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
JP7450995B1 (ja) 2023-04-13 2024-03-18 国立研究開発法人量子科学技術研究開発機構 被験者の脳のタウタンパク質の蓄積量を推定する方法及び装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
CA2178212C (en) 1993-12-21 2011-06-14 Marc Vandermeeren Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
US6121003A (en) 1994-07-29 2000-09-19 Innogentics N.V. Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use
DE60032905T2 (de) 1999-07-06 2007-10-18 Eli Lilly And Co., Indianapolis Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE60141752D1 (de) 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
EP1535930B1 (en) 2002-08-14 2010-10-06 Mitsubishi Chemical Medience Corporation Antibody specific to central nervous system tau protein
EA032675B1 (ru) * 2009-06-10 2019-07-31 Нью-Йорк Юниверсити Способ и композиции для лечения болезни альцгеймера и других таупатий
US8778343B2 (en) 2009-08-28 2014-07-15 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
UA114902C2 (uk) 2011-12-20 2017-08-28 Янссен Байотек, Інк. Виділене антитіло, яке зв'язує парний спіральний філамент-тау (псф-тау), та фармацевтична композиція, що містить таке антитіло
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
LT2935326T (lt) * 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
BR112016030183A2 (pt) * 2014-06-26 2017-11-14 Janssen Vaccines & Prevention Bv anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
MA44955A (fr) * 2015-06-05 2019-03-20 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
US20180186855A1 (en) * 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
CU24538B1 (es) 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7

Also Published As

Publication number Publication date
US10591492B2 (en) 2020-03-17
US20200182888A1 (en) 2020-06-11
KR20200130354A (ko) 2020-11-18
JP2024037794A (ja) 2024-03-19
BR112020018193A2 (pt) 2021-02-02
WO2019171258A1 (en) 2019-09-12
IL277077A (en) 2020-10-29
JP2021517239A (ja) 2021-07-15
EP3762414A1 (en) 2021-01-13
MX2020009278A (es) 2021-01-08
JP7399096B2 (ja) 2023-12-15
CN112105640A (zh) 2020-12-18
PH12020551371A1 (en) 2021-08-23
US10976325B2 (en) 2021-04-13
EP3762414A4 (en) 2022-01-05
CA3093198A1 (en) 2019-09-12
JOP20200216A1 (ar) 2020-09-03
AU2019232630A1 (en) 2020-09-24
SG11202008574VA (en) 2020-10-29
US20200408781A1 (en) 2020-12-31
US20190271710A1 (en) 2019-09-05
MA53338A (fr) 2022-01-05

Similar Documents

Publication Publication Date Title
EA202092087A1 (ru) Анализы для выявления нейродегенеративных заболеваний
Spengler et al. Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in rheumatoid arthritis synovial fluid
DE602005021644D1 (de) Verfahren und reagentien zur diagnose von hantavirusinfektionen
MX344053B (es) Metodos para determinar isotipos de anticuerpos anti-farmacos.
DE60042326D1 (de) Radiomarkierungssatz und bindungstest
EA201992748A1 (ru) Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов
JP2015533788A5 (ru)
RU2013106940A (ru) Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака поджелудочной железы
US20180149598A1 (en) Label-free detection of small and large molecule interactions, and activities in biological systems
MA46814B2 (fr) Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
DE60331677D1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
ATE540979T1 (de) Leptinantagonist und verfahren zur quantitativen messung von leptin
EA202090265A1 (ru) Композиции, способы и/или наборы, содержащие рекомбинантный внеклеточный домен cd38 человека
BR112022000755A2 (pt) Combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento
EP4300101A3 (en) Antigenic peptides and uses thereof for diagnosing and treating autism
WO2021021964A3 (en) Methods of quantifying frataxin and frataxin fusion proteins
BR112021019524A2 (pt) Uso de anticorpo anti-pd-1 na preparação de medicamento para tratamento de tumores sólidos
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
BRPI0610267B8 (pt) métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método
ATE557277T1 (de) Verfahren zur diagnose von endometriose mittels tfpi-2 protein
WO2019118906A3 (en) Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
Gnanapavan et al. Developing biomarkers for MS
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
DE69730223D1 (de) Diagnostische methode zum nachweis von isoformen des eosinophilen kationischen proteins